Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Molnupiravir/nirmatrelvir+ritonavir/remdesivir

Acquired drug resistance and lack of efficacy

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Masuda T, et al. Diverse Gene Mutations by Molnupiravir After B-Cell Depletion Therapy: Report of 2 COVID-19 Cases. American Journal of Respiratory and Critical Care Medicine 207: May 2023. Available from: URL: https://dx.doi.org/10.1164/ajrccm-conference.2023.B61 [abstract] Masuda T, et al. Diverse Gene Mutations by Molnupiravir After B-Cell Depletion Therapy: Report of 2 COVID-19 Cases. American Journal of Respiratory and Critical Care Medicine 207: May 2023. Available from: URL: https://​dx.​doi.​org/​10.​1164/​ajrccm-conference.​2023.​B61 [abstract]
Metadaten
Titel
Molnupiravir/nirmatrelvir+ritonavir/remdesivir
Acquired drug resistance and lack of efficacy
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-55673-5

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Tozinameran

Case report

Multiple drugs

Case report

Multiple drugs